艾塞那肽-话题@MedSci

#艾塞那肽#

36篇内容 | 2588人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2252153, encodeId=9f022252153de, content=<a href='/topic/show?id=a1f9485204d' target=_blank style='color:#2F92EE;'>#帕金森病#</a> <a href='/topic/show?id=4a9886e56ed' target=_blank style='color:#2F92EE;'>#艾塞那肽#</a> <a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=Lancet：GLP-1受体激动剂艾塞那肽能否延缓帕金森病进展？最新研究结果揭晓, objectType=article, longId=863474, objectId=bc0b8634e4cd, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250106/1736135196330_8538692.jpg, objectUrl=/article/show_article.do?id=bc0b8634e4cd, replyNumber=0, likeNumber=26, createdTime=2025-02-16, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=bc0b8634e4cd, moduleTitle=Lancet：GLP-1受体激动剂艾塞那肽能否延缓帕金森病进展？最新研究结果揭晓, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc0b8634e4cd)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2126639, encodeId=32af212663928, content=<a href='/topic/show?id=977a1048622c' target=_blank style='color:#2F92EE;'>#Lecanemab#</a> 治疗<a href='/topic/show?id=3cbe9e7892e' target=_blank style='color:#2F92EE;'>#阿尔茨海默病#</a>，不用说是热点，不过<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>药物<a href='/topic/show?id=4a9886e56ed' target=_blank style='color:#2F92EE;'>#艾塞那肽#</a>治疗<a href='/topic/show?id=a1f9485204d' target=_blank style='color:#2F92EE;'>#帕金森病#</a>; <a href='/topic/show?id=f5cb5192610' target=_blank style='color:#2F92EE;'>#心衰#</a>药物<a href='/topic/show?id=74b24141445' target=_blank style='color:#2F92EE;'>#地高辛#</a>可抑制<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>扩散，这确实令人惊奇！！, objectTitle=Nat Med：2023年11项值得关注的临床试验, objectType=article, longId=758254, objectId=ee06e5825492, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20230111/0c80815cf54e46d09ec9348e80ba2f63.jpg, objectUrl=/article/show_article.do?id=ee06e5825492, replyNumber=0, likeNumber=253, createdTime=2023-04-18, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=香港, moduleDTOList=[ModuleDTO(moduleId=ee06e5825492, moduleTitle=Nat Med：2023年11项值得关注的临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee06e5825492)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1393628, encodeId=73f71393628e6, content=<a href='/topic/show?id=4a9886e56ed' target=_blank style='color:#2F92EE;'>#艾塞那肽#</a>, objectTitle=Cardiovasc Diabetol：达格列净、艾塞那肽及其联合应用于2型糖尿病患者降压作用的机制, objectType=article, longId=726070, objectId=b59ee2607052, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b59ee2607052, replyNumber=0, likeNumber=121, createdTime=2022-05-05, rootId=0, userName=紫砂壶, userId=04c22500137, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b59ee2607052, moduleTitle=Cardiovasc Diabetol：达格列净、艾塞那肽及其联合应用于2型糖尿病患者降压作用的机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b59ee2607052)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1393627, encodeId=f4a2139362e25, content=<a href='/topic/show?id=4a9886e56ed' target=_blank style='color:#2F92EE;'>#艾塞那肽#</a>, objectTitle=Nat Med：2型糖尿病患者皮下注射艾塞那肽与心血管结局, objectType=article, longId=221685, objectId=647c22168537, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=647c22168537, replyNumber=0, likeNumber=111, createdTime=2021-12-09, rootId=0, userName=紫砂壶, userId=04c22500137, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=647c22168537, moduleTitle=Nat Med：2型糖尿病患者皮下注射艾塞那肽与心血管结局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=647c22168537)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1393626, encodeId=2f0513936263b, content=<a href='/topic/show?id=4a9886e56ed' target=_blank style='color:#2F92EE;'>#艾塞那肽#</a>, objectTitle=Diabetes Obes Metab：每日三次的基础胰岛素治疗中加入短效艾塞那肽对1型糖尿病患者骨代谢的影响, objectType=article, longId=220047, objectId=feb722004e41, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=feb722004e41, replyNumber=0, likeNumber=104, createdTime=2021-11-11, rootId=0, userName=紫砂壶, userId=04c22500137, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=feb722004e41, moduleTitle=Diabetes Obes Metab：每日三次的基础胰岛素治疗中加入短效艾塞那肽对1型糖尿病患者骨代谢的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=feb722004e41)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1393625, encodeId=1ad413936253d, content=<a href='/topic/show?id=4a9886e56ed' target=_blank style='color:#2F92EE;'>#艾塞那肽#</a>, objectTitle=Diabetes Obes Metab：每日2次艾塞那肽和达格列净单药或联合治疗对2型糖尿病肥胖患者肾功能标志物的影响, objectType=article, longId=219738, objectId=782b219e38c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=782b219e38c6, replyNumber=0, likeNumber=66, createdTime=2021-11-05, rootId=0, userName=紫砂壶, userId=04c22500137, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=782b219e38c6, moduleTitle=Diabetes Obes Metab：每日2次艾塞那肽和达格列净单药或联合治疗对2型糖尿病肥胖患者肾功能标志物的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=782b219e38c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1393624, encodeId=070313936243f, content=<a href='/topic/show?id=4a9886e56ed' target=_blank style='color:#2F92EE;'>#艾塞那肽#</a>, objectTitle=Diabetes Care：“明星药”GLP-1 RA艾塞那肽对2型糖尿病患者颈动脉硬化的影响, objectType=article, longId=213293, objectId=30d2213293d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30d2213293d8, replyNumber=0, likeNumber=92, createdTime=2021-06-28, rootId=0, userName=紫砂壶, userId=04c22500137, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30d2213293d8, moduleTitle=Diabetes Care：“明星药”GLP-1 RA艾塞那肽对2型糖尿病患者颈动脉硬化的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30d2213293d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1393623, encodeId=56c2139362380, content=<a href='/topic/show?id=4a9886e56ed' target=_blank style='color:#2F92EE;'>#艾塞那肽#</a>, objectTitle=Pediatr Obes：每周使用艾塞那肽可有效且安全的治疗青少年严重肥胖症, objectType=article, longId=210985, objectId=24942109855a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24942109855a, replyNumber=0, likeNumber=93, createdTime=2021-05-10, rootId=0, userName=紫砂壶, userId=04c22500137, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24942109855a, moduleTitle=Pediatr Obes：每周使用艾塞那肽可有效且安全的治疗青少年严重肥胖症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24942109855a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1393622, encodeId=8b9b139362266, content=<a href='/topic/show?id=4a9886e56ed' target=_blank style='color:#2F92EE;'>#艾塞那肽#</a>, objectTitle=Diabetologia：艾塞那肽注射液PB-119可有效治疗未治疗过的2型糖尿病, objectType=article, longId=208248, objectId=ad3e208248d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad3e208248d6, replyNumber=0, likeNumber=97, createdTime=2021-03-12, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad3e208248d6, moduleTitle=Diabetologia：艾塞那肽注射液PB-119可有效治疗未治疗过的2型糖尿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad3e208248d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1393621, encodeId=fb131393621c3, content=<a href='/topic/show?id=4a9886e56ed' target=_blank style='color:#2F92EE;'>#艾塞那肽#</a>, objectTitle=Lancet Diabetes Endo：艾塞那肽不能作为I型糖尿病患者胰岛素治疗的辅助治疗手段, objectType=article, longId=189281, objectId=367918928117, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=367918928117, replyNumber=0, likeNumber=85, createdTime=2020-03-05, rootId=0, userName=紫砂壶, userId=04c22500137, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=367918928117, moduleTitle=Lancet Diabetes Endo：艾塞那肽不能作为I型糖尿病患者胰岛素治疗的辅助治疗手段, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=367918928117)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1393620, encodeId=4754139362073, content=<a href='/topic/show?id=4a9886e56ed' target=_blank style='color:#2F92EE;'>#艾塞那肽#</a>, objectTitle=Circulation：艾塞那肽对有无心衰的2型糖尿病患者的心血管预后的影响, objectType=article, longId=183077, objectId=7c601830e742, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c601830e742, replyNumber=0, likeNumber=0, createdTime=2019-11-17, rootId=0, userName=紫砂壶, userId=04c22500137, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c601830e742, moduleTitle=Circulation：艾塞那肽对有无心衰的2型糖尿病患者的心血管预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c601830e742)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1393619, encodeId=fa8213936192d, content=<a href='/topic/show?id=4a9886e56ed' target=_blank style='color:#2F92EE;'>#艾塞那肽#</a>, objectTitle=JAHA：艾塞那肽对高心血管风险2型糖尿病患者的疗效研究, objectType=article, longId=149505, objectId=f36714950581, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f36714950581, replyNumber=0, likeNumber=181, createdTime=2018-09-26, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f36714950581, moduleTitle=JAHA：艾塞那肽对高心血管风险2型糖尿病患者的疗效研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f36714950581)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1393618, encodeId=3e6313936188d, content=<a href='/topic/show?id=4a9886e56ed' target=_blank style='color:#2F92EE;'>#艾塞那肽#</a>, objectTitle=Diabetes Obes Metab：2型糖尿病患者附加治疗：艾塞那肽每天两次vs甘精胰岛素每天一次, objectType=article, longId=124976, objectId=d83e1249e6f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d83e1249e6f4, replyNumber=0, likeNumber=94, createdTime=2017-12-30, rootId=0, userName=紫砂壶, userId=04c22500137, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d83e1249e6f4, moduleTitle=Diabetes Obes Metab：2型糖尿病患者附加治疗：艾塞那肽每天两次vs甘精胰岛素每天一次, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d83e1249e6f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1393617, encodeId=f5e7139361e48, content=<a href='/topic/show?id=4a9886e56ed' target=_blank style='color:#2F92EE;'>#艾塞那肽#</a>, objectTitle=Anesthesiology：静脉艾塞那肽对冠脉搭桥术后患者围手术期血糖控制的疗效：Ⅱ期/Ⅲ期随机试验, objectType=article, longId=120518, objectId=e884120518a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e884120518a2, replyNumber=0, likeNumber=125, createdTime=2017-11-19, rootId=0, userName=紫砂壶, userId=04c22500137, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e884120518a2, moduleTitle=Anesthesiology：静脉艾塞那肽对冠脉搭桥术后患者围手术期血糖控制的疗效：Ⅱ期/Ⅲ期随机试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e884120518a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1393616, encodeId=86fb13936168f, content=<a href='/topic/show?id=4a9886e56ed' target=_blank style='color:#2F92EE;'>#艾塞那肽#</a>, objectTitle=FDA：2型糖尿病患者每周注射一次艾塞那肽，血糖有望恢复正常, objectType=article, longId=117519, objectId=159711e51972, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=159711e51972, replyNumber=0, likeNumber=80, createdTime=2017-10-27, rootId=0, userName=紫砂壶, userId=04c22500137, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=159711e51972, moduleTitle=FDA：2型糖尿病患者每周注射一次艾塞那肽，血糖有望恢复正常, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=159711e51972)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1393615, encodeId=c3cb1393615b1, content=<a href='/topic/show?id=4a9886e56ed' target=_blank style='color:#2F92EE;'>#艾塞那肽#</a>, objectTitle=Diabetes Obes Metab:肥胖成人：达格列净每天一次+艾塞那肽每周一次效果如何？, objectType=article, longId=116833, objectId=38d311683307, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=38d311683307, replyNumber=0, likeNumber=101, createdTime=2017-10-21, rootId=0, userName=紫砂壶, userId=04c22500137, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=38d311683307, moduleTitle=Diabetes Obes Metab:肥胖成人：达格列净每天一次+艾塞那肽每周一次效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=38d311683307)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1393614, encodeId=e285139361404, content=<a href='/topic/show?id=4a9886e56ed' target=_blank style='color:#2F92EE;'>#艾塞那肽#</a>, objectTitle=NEJM：每周一次艾塞那肽治疗对2型糖尿病患者的心血管预后, objectType=article, longId=115856, objectId=886411585609, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=886411585609, replyNumber=0, likeNumber=102, createdTime=2017-10-13, rootId=0, userName=紫砂壶, userId=04c22500137, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=886411585609, moduleTitle=NEJM：每周一次艾塞那肽治疗对2型糖尿病患者的心血管预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=886411585609)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1393613, encodeId=d32e139361324, content=<a href='/topic/show?id=4a9886e56ed' target=_blank style='color:#2F92EE;'>#艾塞那肽#</a>, objectTitle=NEJM:经证实艾塞那肽可治疗糖尿病，不会引发并发症, objectType=article, longId=113054, objectId=d223113054c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d223113054c7, replyNumber=0, likeNumber=84, createdTime=2017-09-18, rootId=0, userName=紫砂壶, userId=04c22500137, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d223113054c7, moduleTitle=NEJM:经证实艾塞那肽可治疗糖尿病，不会引发并发症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d223113054c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1393612, encodeId=0e781393612af, content=<a href='/topic/show?id=4a9886e56ed' target=_blank style='color:#2F92EE;'>#艾塞那肽#</a>, objectTitle=Diabetes Obes Metab：考虑医疗资源使用和成本降糖应选艾塞那肽还是基础胰岛素？, objectType=article, longId=111950, objectId=8bf9111950c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8bf9111950c2, replyNumber=0, likeNumber=99, createdTime=2017-09-06, rootId=0, userName=紫砂壶, userId=04c22500137, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8bf9111950c2, moduleTitle=Diabetes Obes Metab：考虑医疗资源使用和成本降糖应选艾塞那肽还是基础胰岛素？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8bf9111950c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1393611, encodeId=07ea1393611bd, content=<a href='/topic/show?id=4a9886e56ed' target=_blank style='color:#2F92EE;'>#艾塞那肽#</a>, objectTitle=The Lancet：糖尿病药物艾塞那肽新发现, objectType=article, longId=107964, objectId=638610e96491, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=638610e96491, replyNumber=0, likeNumber=94, createdTime=2017-08-09, rootId=0, userName=紫砂壶, userId=04c22500137, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=638610e96491, moduleTitle=The Lancet：糖尿病药物艾塞那肽新发现, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=638610e96491)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

艾塞那肽

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#帕金森病# #艾塞那肽# #GLP-1受体激动剂#

Lancet：GLP-1受体激动剂艾塞那肽能否延缓帕金森病进展？最新研究结果揭晓

2025-02-16发表于陕西省

侠胆医心 (审核中...)

前往app查看评论内容

#Lecanemab# 治疗#阿尔茨海默病#，不用说是热点，不过#糖尿病#药物#艾塞那肽#治疗#帕金森病#; #心衰#药物#地高辛#可抑制#乳腺癌#扩散，这确实令人惊奇！！

Nat Med：2023年11项值得关注的临床试验

2023-04-18发表于香港

紫砂壶 (审核中...)

前往app查看评论内容

#艾塞那肽#

Cardiovasc Diabetol：达格列净、艾塞那肽及其联合应用于2型糖尿病患者降压作用的机制

2022-05-05

紫砂壶 (审核中...)

前往app查看评论内容

#艾塞那肽#

Nat Med：2型糖尿病患者皮下注射艾塞那肽与心血管结局

2021-12-09

紫砂壶 (审核中...)

前往app查看评论内容

#艾塞那肽#

Diabetes Obes Metab：每日三次的基础胰岛素治疗中加入短效艾塞那肽对1型糖尿病患者骨代谢的影响

2021-11-11

紫砂壶 (审核中...)

前往app查看评论内容

#艾塞那肽#

Diabetes Obes Metab：每日2次艾塞那肽和达格列净单药或联合治疗对2型糖尿病肥胖患者肾功能标志物的影响

2021-11-05

紫砂壶 (审核中...)

前往app查看评论内容

#艾塞那肽#

Diabetes Care：“明星药”GLP-1 RA艾塞那肽对2型糖尿病患者颈动脉硬化的影响

2021-06-28

紫砂壶 (审核中...)

前往app查看评论内容

#艾塞那肽#

Pediatr Obes：每周使用艾塞那肽可有效且安全的治疗青少年严重肥胖症

2021-05-10

爆笑小医 (审核中...)

前往app查看评论内容

#艾塞那肽#

Diabetologia：艾塞那肽注射液PB-119可有效治疗未治疗过的2型糖尿病

2021-03-12

紫砂壶 (审核中...)

前往app查看评论内容

#艾塞那肽#

Lancet Diabetes Endo：艾塞那肽不能作为I型糖尿病患者胰岛素治疗的辅助治疗手段

2020-03-05

紫砂壶 (审核中...)

前往app查看评论内容

#艾塞那肽#

Circulation：艾塞那肽对有无心衰的2型糖尿病患者的心血管预后的影响

2019-11-17

docwu2019 (审核中...)

前往app查看评论内容

#艾塞那肽#

JAHA：艾塞那肽对高心血管风险2型糖尿病患者的疗效研究

2018-09-26

紫砂壶 (审核中...)

前往app查看评论内容

#艾塞那肽#

Diabetes Obes Metab：2型糖尿病患者附加治疗：艾塞那肽每天两次vs甘精胰岛素每天一次

2017-12-30

紫砂壶 (审核中...)

前往app查看评论内容

#艾塞那肽#

Anesthesiology：静脉艾塞那肽对冠脉搭桥术后患者围手术期血糖控制的疗效：Ⅱ期/Ⅲ期随机试验

2017-11-19

紫砂壶 (审核中...)

前往app查看评论内容

#艾塞那肽#

FDA：2型糖尿病患者每周注射一次艾塞那肽，血糖有望恢复正常

2017-10-27

紫砂壶 (审核中...)

前往app查看评论内容

#艾塞那肽#

Diabetes Obes Metab:肥胖成人：达格列净每天一次+艾塞那肽每周一次效果如何？

2017-10-21

紫砂壶 (审核中...)

前往app查看评论内容

#艾塞那肽#

NEJM：每周一次艾塞那肽治疗对2型糖尿病患者的心血管预后

2017-10-13

紫砂壶 (审核中...)

前往app查看评论内容

#艾塞那肽#

NEJM:经证实艾塞那肽可治疗糖尿病，不会引发并发症

2017-09-18

紫砂壶 (审核中...)

前往app查看评论内容

#艾塞那肽#

Diabetes Obes Metab：考虑医疗资源使用和成本降糖应选艾塞那肽还是基础胰岛素？

2017-09-06

紫砂壶 (审核中...)

前往app查看评论内容

#艾塞那肽#

The Lancet：糖尿病药物艾塞那肽新发现

2017-08-09

科室
- - 订阅+
  - 更多科室
工具
服务